Damora Therapeutics Q3 net loss widens to $31.99 million

Bitget2026/11/04 21:34

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Damora Therapeutics’ third-quarter 2026 net loss widened to $32 million from a year earlier.
Research and development expenses rose to $25.5 million, while general and administrative expenses increased to $11.4 million.
Cash, cash equivalents and marketable securities totaled $528.5 million at September 30, expected to fund operations into the second half of 2029.
FDA clearance enabled U.S. initiation of the CLARITY-101 trial; two clinical proof-of-concept datasets are expected beginning mid-2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Damora Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611041606PRIMZONEFULLFEED9870572) on November 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Damora Therapeutics Q3 net loss widens to $31.99 million

You may also like

Crypto prices